💬 Income investors: Would you trust BMY’s 4.4% yield, or does the patent cliff scare you off? Let’s debate!
For investors in 2026, buying dividend stocks has become a core strategy. These stocks offer value not only through steady income but also stability — they are often seen as relatively safe, buy-and-hold investments. However, when a stock boasts a 4.4% dividend yield — far above the S&P 500 average of just 1.2% — investors should pause and ask: Is this payout really sustainable?
$Bristol-Myers Squibb(BMY)$is exactly that eye-catching pharmaceutical stock. As a healthcare leader, its current 4.4% yield looks highly attractive in today’s market. At first glance, it seems like an obvious dividend pick. But investors often make a critical mistake when evaluating dividend stocks: focusing too heavily on past performance.
Even the strongest dividend growth streaks can end, and policies can shift during tough times — especially when a company faces serious challenges and must redirect cash to more urgent priorities.
The Patent Cliff: A Sword Hanging Over the Dividend
Bristol Myers Squibb’s path ahead is far from smooth. The company is facing a looming patent cliff for several key drugs, including blockbuster blood thinner Eliquis and star oncology drug Opdivo.
Rising generic competition will likely hit revenue hard, leading to lower profits and shrinking free cash flow — directly threatening the company’s ability to maintain its dividend. To soften the blow from expiring patents, the firm may be forced to pursue acquisitions, putting even more strain on cash flow.
Signs of pressure are already here:
-
Last year’s revenue: $48.2 billion, flat year over year
-
2026 revenue guidance: $46.0–$47.5 billion, implying a decline
On the surface, BMY still looks like a dividend investor’s dream:
-
17 consecutive years of dividend increases
-
A payout ratio around 72%, considered manageable
-
A very high yield
Yet significant uncertainty surrounding the business cannot be ignored. While a dividend cut or suspension is not certain, it is a real possibility given the headwinds the company could face in the coming years.
The ideal dividend stock is one you can “buy and forget” without constant worry. Bristol Myers Squibb, right now, clearly does not fit that description.
Conclusion: Beyond High Yield, Stability Matters Most
Today’s markets are rocked by trade wars, geopolitical tension, inflation fears, and recession worries. In this environment, stable, through-the-cycle companies deserve heavy attention.
But BMY’s story reminds us:
A high dividend yield is attractive, but the business fundamentals supporting the payout are what truly matter.
Under the shadow of a major patent cliff, whether this 4.4% high-yield stock can keep its dividend stable remains a question only time will answer.
For SG users only, Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with unlimited trading on SG, HK, and US stocks, as well as ETFs.
🎉Cash Boost Account Now Supports 35,000+ Stocks & ETFs – Greater Flexibility Now
Find out more here.
Complete your first Cash Boost Account trade with a trade amount of ≥ SGD1000* to get SGD 688 stock vouchers*! The trade can be executed using any payment type available under the Cash Boost Account: Cash, CPF, SRS, or CDP.
Other helpful links:
Comments